Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

Tools

Item Type:	Article
Title:	Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange
Creators Name:	Kühne, L., Knoebl, P., Eller, K., Thaler, J., Sperr, W.R., Gleixner, K.V., Osterholt, T., Kaufeld, J.K., Menne, J., Buxhofer-Ausch, V., Mühlfeld, A.S., Seelow, E., Schreiber, A., Todorova, P., Cukoski, S., Jabs, W.J., Özcan, F., Gäckler, A., Schönfelder, K., Seibert, F.S., Westhoff, T.H., Schwenger, V., Eichenauer, D.A., Völker, L. and Brinkkoetter, P.
Abstract:	Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening autoimmune disorder caused by ADAMTS13 deficiency. Caplacizumab, an anti-VWF nanobody, is approved for iTTP treatment, reducing the need for therapeutic plasma exchange (TPE) and improving platelet count recovery and survival. We conducted a retrospective study on 42 acute iTTP cases in Austria and Germany, treated with a modified regimen aimed at avoiding TPE if platelet count increased after the first caplacizumab dose. Baseline characteristics and patient outcomes were compared with a control group of 59 patients with iTTP, receiving frontline treatment with TPE, caplacizumab, and immunosuppression. The main outcome was the time to platelet count normalization. Secondary outcomes included clinical response, exacerbation, refractory iTTP, iTTP-related deaths, and the time to platelet count doubling. The median time to platelet count normalization was similar between the two cohorts (3 and 4 days; P = 0.31). There were no significant differences in clinical response, exacerbations, refractoriness, iTTP-related deaths, or time to platelet count doubling reflecting the short-term treatment response. Four patients did not respond to the first caplacizumab dose and TPE was subsequently initiated. Cytomegalovirus infection, HIV/hepatitis B co-infection, an ovarian teratoma with associated anti-platelet antibodies, and multiple platelet transfusion before the correct diagnosis may have impeded immediate treatment response in these patients. In conclusion, caplacizumab and immunosuppression alone, without TPE, rapidly controlled thrombotic microangiopathy and achieved a sustained clinical response in iTTP. Our study provides a basis for TPE-free iTTP management in experienced centers via shared decision-making between patients and treating physicians.
Source:	Blood
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date:	5 June 2024
Official Publication:	https://doi.org/10.1182/blood.2023023780
PubMed:	View item in PubMed

Repository Staff Only: item control page